NDAINTRAVENOUSSOLUTION
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE (clindamycin phosphate) by Baxter International is 12. First approved in 2017.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Clindamycin phosphate in 0.9% sodium chloride is an intravenous antibacterial solution containing clindamycin, a lincosamide antibiotic. It works by inhibiting bacterial protein synthesis and is used to treat infections caused by susceptible aerobic and anaerobic pathogens. The prodrug formulation is rapidly converted to active clindamycin in serum, achieving peak concentrations within minutes of IV infusion.
Peak
Product is at peak lifecycle stage, indicating stable market presence with established commercial infrastructure supporting Brand, Sales, and Medical Affairs teams.
Mechanism of Action
12.1 Mechanism of Action Clindamycin is an antibacterial drug [see ] . 12.3 Pharmacokinetics Clindamycin phosphate is a water-soluble ester prodrug of clindamycin. Biologically inactive clindamycin phosphate is converted to active clindamycin. By the end of short-term intravenous infusion, peak…
Worked on CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.